Skip to main content
VIYASH SCIENTIFIC LIMITED logo

VIYASH SCIENTIFIC LIMITED — Investor Relations & Filings

Ticker · VIYASH ISIN · INE807F01027 LEI · 335800SXM7D3VSHF2X07 BSE.NS Manufacturing
Open in API
Filings indexed 1,420 across all filing types
Latest filing 2025-11-14 Regulatory Filings
Country IN India
Listing BSE.NS VIYASH

About VIYASH SCIENTIFIC LIMITED

https://www.viyash.com

Viyash Scientific Limited is an integrated pharmaceutical platform specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage forms. The organization operates a network of manufacturing facilities supported by robust research and development capabilities, focusing on complex chemistry and niche therapeutic segments. Its core business activities encompass the entire pharmaceutical value chain, from process development and scale-up to commercial-scale production. The company provides integrated solutions to global partners, leveraging its technical expertise in chemical synthesis and commitment to international quality standards. By maintaining a focus on operational excellence and innovation, the company serves as a strategic partner in the global healthcare supply chain, delivering high-quality medicinal components and formulations.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2025-11-14 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 90% confidence The document is titled as the Outcome of Board Meeting held on November 14, 2025, enclosing the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025, together with the Independent Auditor’s Limited Review Report. It contains full interim financial statements and auditor’s review, matching the definition of an Interim / Quarterly Report under our taxonomy. H1 2026
2025-11-14 English
Q2 FY26 Results
Interim / Quarterly Report Classification · 85% confidence The document is an official outcome of the Board meeting announcing and enclosing the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, accompanied by the Independent Auditor’s Limited Review Report. It contains actual interim financial statements and auditor review procedures as required under SEBI Listing Regulations, which corresponds to a comprehensive interim/quarterly report rather than a simple press release or notice. Therefore, it should be classified as an Interim / Quarterly Report. H1 2026
2025-11-14 English
Allotment of Equity Shares under Sequent Scientific Limited Employee Stock Option Plan 2020.
Share Issue/Capital Change Classification · 100% confidence The document is a formal letter addressed to stock exchanges informing about the allotment of equity shares under an Employee Stock Option Plan (ESOP). It details the number of shares allotted, the exercise price, and the resulting increase in the company's paid-up equity share capital. There are no financial statements, quarterly or annual results, or management discussions. The document is an announcement of a capital change related to share allotment under ESOP. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2025-11-11 English
General Updates
Share Issue/Capital Change Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the allotment of equity shares under an Employee Stock Option Plan (ESOP). It details the number of shares allotted, the exercise price, and the resulting increase in the company's paid-up equity share capital. There are no financial statements, earnings data, or management discussion. The document is an announcement of a capital change due to share allotment under ESOP. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2025-11-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation of a scheduled conference call to discuss Q2FY26 financial results, sent to stock exchanges as per regulatory requirements. It includes details about the call date, time, speakers, and dial-in information. The document does not contain actual financial data or a transcript of the call, but rather serves as a notification of the upcoming earnings call. Therefore, it is classified as a Call Transcript (CT) related announcement, but since it is only the intimation and not the transcript itself, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the call. The document length is short (2226 characters), and it does not contain financial statements or detailed analysis, so it is not an Earnings Release (ER) or Interim Report (IR).
2025-11-11 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.